A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China

Active, not recruitingOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Diabetic Macular Edema
Trial Locations (13)

100034

Peking University People'S Hospital /ID# 274505, Beijing

116000

The First Affiliated Hospital of Dalian Medical University /ID# 270563, Dalian

200080

Shanghai General hospital /ID# 270376, Shanghai

266071

Qingdao Eye Hospital Of Shandong First Medical University /ID# 268173, Qingdao

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 273617, Hangzhou

325027

The Affiliated Eye Hospital Of Wenzhou Medical University /ID# 274466, Wenzhou

390000

Xiamen Eye Center of Xiamen University /ID# 268172, Xiamen

430000

General Hospital of Central Theater Command /ID# 273618, Wuhan

450003

Henan Provincial Eye Hosptial /ID# 272424, Zhengzhou

510623

Zhongshan Ophthalmic Center,SunYat-Sen University /ID# 274555, Guangzhou

610041

West China Hospital of Sichuan University /ID# 273656, Chengdu

710004

Xi'an Fourth Hospital /ID# 270562, Xi'an

030072

Shanxi Eye Hospital /ID# 270564, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY